This document introduces an antimicrobial biofilm wound gel called BLASTX. It summarizes that biofilms are communities of bacteria embedded in a protective matrix that cause chronic infections by blocking antimicrobial penetration. BLASTX works by deconstructing the biofilm matrix, destroying pathogens, and preventing reformation through a proprietary technology. It has broad-spectrum activity against bacteria and fungi commonly found in wounds. Studies show BLASTX, when used in combination with standard of care, reduces wound size and increases healing rates by disrupting the biofilm.
BioShield 75 And Biofilm Prevention MwbsSkip Bryan
Discover how to keep your home, school or office free from Swine Flu, MRSA, Staph, Mold and more with BioShield 75 surface protectant. Long lasting, inexpensive, non-toxic and easy to apply, see how simple it is to protect yourself and those you love with BioShield 75.
BioShield 75 And Biofilm Prevention MwbsSkip Bryan
Discover how to keep your home, school or office free from Swine Flu, MRSA, Staph, Mold and more with BioShield 75 surface protectant. Long lasting, inexpensive, non-toxic and easy to apply, see how simple it is to protect yourself and those you love with BioShield 75.
Vaccines are designed to elicit an immune response against the particular microbe or bits of the microbe from which the vaccine is made. This idea dates back several centuries, when British surgeon, Edward Jenner developed the first vaccine against a lethal infectious disease, small pox. Between the 18th century and now, more than 65 products have been approved which, together with public health and other developments, have contributed to the tapering and, in some cases, eradication of infectious diseases that used to kill millions. The problem is that the design is based on the physical attributes of the microbe. So, one person might be infected with virus x, which mutates rapidly to become 10 or more different strains. So, between approval and reaching the public, effectiveness may drop or wane over time. The sheer logistics of designing a trial means that follow-up periods are not long enough to account for every possible safety issue. Nevertheless, they remain our go-to defense for lethal infections, such as Ebola, and ones that reduce productivity. In other cases, timely inoculations may protect against the risk of developing specific cancers later in life. They have also contributed to the fact that most people are not at home sick with polio or some of the other ancient plagues.
However, anti-infective vaccines are typically given to healthy children and people on the basis that it will not make them sick or that it will reduce the risk of premature death. Because vaccines need to be preserved, properly stored and kept free of other contamination before it reaches many distribution sites, other ingredients are added to the mix. And some people, especially those with weakened immune systems, may have severe/life-threatening allergies to additives or a contaminated batch.
So, one in a million complications/deaths is one in a million too many. To this end, I have compiled a summary culled from various sources, to foster a positive dialogue towards improvements.
An Innovative Approach to Fighting Healthcare-associated Infections (HAIs)life-threads
Life Threads is dedicated to having an impact on healthcare-associated infections (HAIs). The company manufactures and distributes a “first of its kind” product line of professional medical apparel, patient garments and related items treated with an EPA-registered antimicrobial active ingredient and binding agents that protects the fabric from harmful pathogens found within institutional medical environments.
An Innovative Approach to Fighting Healthcare-associated Infections (HAIs)life-threads
Life Threads is dedicated to having an impact on healthcare-associated infections (HAIs). The company manufactures and distributes a “first of its kind” product line of professional medical apparel, patient garments and related items treated with an EPA-registered antimicrobial active ingredient and binding agents that protects the fabric from harmful pathogens found within institutional medical environments.
There are many studies about bacterial and fungal biofilm which they were considered a very big problem now days ,because of that it was one of the most virulence factors which in turns increased resistant for antibiotics
Bacterial biofilms are complex surface attached communities of bacteria held together by self-produced polymer matrixs mainly composed of polysaccharides, secreted proteins, and extracellular DNAs
A biofilm can consist of a single microbial species or a combination of different species of bacteria, protozoa, archaea, algae, filamentous fungi, and yeast that strongly attach to each other and to biotic or abiotic surfaces
bacterial biofilm formation relies on the interaction between the bacterial cells, the substrates and the surrounding media . And the formation of bacterial biofilms is a multi-step process starting with reversible attachment to surfaces aided by intermolecular forces and hydrophobicity, and then progress to extracellular polymeric substances (EPS) production which enable the cells to permanently adhere to a surface.
there are five main phases involved in the biofilm formation process:
reversible attachment
irreversible attachment
EPS production
maturation of biofilm
dispersal/detachment
Alan Lesniewicz Memorial Lecture at UIC - July 2015Cassandra Quave
This is the keynote lecture given at the University of Illinois at Chicago Garden Walk event in the department of Pharmacognosy. The objectives of the talk were:
·Discuss the role of medical ethnobotany in drug discovery efforts
·Explore state-of-the-art research techniques that examine the activity of botanical natural products with next generation antibiotic discovery efforts focused on “alternative targets”, such as bacterial communication systems
·Provide examples of current research underway by her group both in the field (especially through fieldwork in the Mediterranean) and the lab (natural product research on multidrug resistant bacteria).
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
Vaccines are designed to elicit an immune response against the particular microbe or bits of the microbe from which the vaccine is made. This idea dates back several centuries, when British surgeon, Edward Jenner developed the first vaccine against a lethal infectious disease, small pox. Between the 18th century and now, more than 65 products have been approved which, together with public health and other developments, have contributed to the tapering and, in some cases, eradication of infectious diseases that used to kill millions. The problem is that the design is based on the physical attributes of the microbe. So, one person might be infected with virus x, which mutates rapidly to become 10 or more different strains. So, between approval and reaching the public, effectiveness may drop or wane over time. The sheer logistics of designing a trial means that follow-up periods are not long enough to account for every possible safety issue. Nevertheless, they remain our go-to defense for lethal infections, such as Ebola, and ones that reduce productivity. In other cases, timely inoculations may protect against the risk of developing specific cancers later in life. They have also contributed to the fact that most people are not at home sick with polio or some of the other ancient plagues.
However, anti-infective vaccines are typically given to healthy children and people on the basis that it will not make them sick or that it will reduce the risk of premature death. Because vaccines need to be preserved, properly stored and kept free of other contamination before it reaches many distribution sites, other ingredients are added to the mix. And some people, especially those with weakened immune systems, may have severe/life-threatening allergies to additives or a contaminated batch.
So, one in a million complications/deaths is one in a million too many. To this end, I have compiled a summary culled from various sources, to foster a positive dialogue towards improvements.
An Innovative Approach to Fighting Healthcare-associated Infections (HAIs)life-threads
Life Threads is dedicated to having an impact on healthcare-associated infections (HAIs). The company manufactures and distributes a “first of its kind” product line of professional medical apparel, patient garments and related items treated with an EPA-registered antimicrobial active ingredient and binding agents that protects the fabric from harmful pathogens found within institutional medical environments.
An Innovative Approach to Fighting Healthcare-associated Infections (HAIs)life-threads
Life Threads is dedicated to having an impact on healthcare-associated infections (HAIs). The company manufactures and distributes a “first of its kind” product line of professional medical apparel, patient garments and related items treated with an EPA-registered antimicrobial active ingredient and binding agents that protects the fabric from harmful pathogens found within institutional medical environments.
There are many studies about bacterial and fungal biofilm which they were considered a very big problem now days ,because of that it was one of the most virulence factors which in turns increased resistant for antibiotics
Bacterial biofilms are complex surface attached communities of bacteria held together by self-produced polymer matrixs mainly composed of polysaccharides, secreted proteins, and extracellular DNAs
A biofilm can consist of a single microbial species or a combination of different species of bacteria, protozoa, archaea, algae, filamentous fungi, and yeast that strongly attach to each other and to biotic or abiotic surfaces
bacterial biofilm formation relies on the interaction between the bacterial cells, the substrates and the surrounding media . And the formation of bacterial biofilms is a multi-step process starting with reversible attachment to surfaces aided by intermolecular forces and hydrophobicity, and then progress to extracellular polymeric substances (EPS) production which enable the cells to permanently adhere to a surface.
there are five main phases involved in the biofilm formation process:
reversible attachment
irreversible attachment
EPS production
maturation of biofilm
dispersal/detachment
Alan Lesniewicz Memorial Lecture at UIC - July 2015Cassandra Quave
This is the keynote lecture given at the University of Illinois at Chicago Garden Walk event in the department of Pharmacognosy. The objectives of the talk were:
·Discuss the role of medical ethnobotany in drug discovery efforts
·Explore state-of-the-art research techniques that examine the activity of botanical natural products with next generation antibiotic discovery efforts focused on “alternative targets”, such as bacterial communication systems
·Provide examples of current research underway by her group both in the field (especially through fieldwork in the Mediterranean) and the lab (natural product research on multidrug resistant bacteria).
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
Explore our infographic on 'Essential Metrics for Palliative Care Management' which highlights key performance indicators crucial for enhancing the quality and efficiency of palliative care services.
This visual guide breaks down important metrics across four categories: Patient-Centered Metrics, Care Efficiency Metrics, Quality of Life Metrics, and Staff Metrics. Each section is designed to help healthcare professionals monitor and improve care delivery for patients facing serious illnesses. Understand how to implement these metrics in your palliative care practices for better outcomes and higher satisfaction levels.
3. Antimicrobial Biofilm Wound Gel
What is Biofilm?
Percival SL, Vuotto C, Donelli G, Lipsky BA. Biofilms and wounds: an identification algorithm and potential treatment options. Adv Wound Care (New Rochelle). 2015;4(7):389
Biofilms are powerful communities of bacteria that function as a single entity with
behaviours and defences that can produce chronic and recurrent infections.
These bacteria are protected within a matrix, surrounded by a defensive “slime”
layer, called the Extracellular Polymeric Substance (EPS) that adheres to
surfaces and forms biofilms.
Only 10% to 20% of a wound biofilm is composed of microorganisms; the other
80% to 90% is EPS.
The EPS acts as a physical barrier obstructing the penetration of antimicrobials,
and obstructing host defences, making it difficult for such treatments to reach the
biofilm bacteria for eradication and removal.
4. Antimicrobial Biofilm Wound Gel
BACTERIA – Planktonic and Biofilm Matrixed
10%
90% of bacteria exist in
biofilms structure
of bacteria are
planktonic/ free-floating
5. Antimicrobial Biofilm Wound Gel
Where is it – Biofilm
Biofilms form within 5-10
mins after suture
Evidence has shown that biofilms exist in at
least 5 different locations in wounds:
Did you know?
Within the wound bed
Within deep tissue
Within and on slough
Within and on necrotic tissue
Wound dressings
6. Antimicrobial Biofilm Wound Gel
Biofilm involved 90% chronic infections
Microbial Biofilm Lifecycle
Biofilms are persistent
Biofilm Development
Individual microbes
Patient Quality of Life
HCP time and financial impact
Significantly delay wound healing
We can’t see them
Biofilms reform within 5 mins
Mature biofilms spawn new colonies
Location of biofilm attachment (catheters,
devices, dressings)
Hyperinflammation
Host immunity
7. Antimicrobial Biofilm Wound Gel
• Infection
• Pain
• Malodour
IDF . IDF Diabetes Atlas. 9th ed. International Diabetes Federation; Brussels, Belgium: 2019
Impact of Biofilm
• Highly stressful
• Isolating
• Debilitating/Loss of function
• Extended hospital stay
• Increased cost
• Social and family impact
Individuals also live in fear of
recurrence and complications
Clinical impact
Patient impact
8. Antimicrobial Biofilm Wound Gel
By 2050 infection will be the largest cause of worldwide death1
10 million people
will die every year due to
antimicrobial resistance (AMR)
Biofilm influences 65%
of all microbial infections, and
85% of all chronic infections
Pathogenic
Biofilm
Drives AMR
doi.org/10.1016/S0140-6736(21)02724-0 Bull World Health Organ. 2016 Sep 1;94(9):638-639. doi: 10.2471/BLT.16.020916. Erratum in: Bull World Health Organ. 2016 Oct 1;94(10 ):784. PMID: 27708467; PMCID:
PMC5034641. Malone M. et al. The prevalence of biofilms in chronic wounds: a systematic review and meta-analysis of published data. J Wound Care 2017: 26(1): 20-25
Biofilm’s role in resistance
Biofilm contribute to
phenotypic resistance
Biofilm is physical barrier to
antimicrobials
Treating biofilm could be a key
factor in pushing the wound
toward a healing state
9.
10. Antimicrobial Biofilm Wound Gel
The BLASTX patient
BLASTX is Medsafe and TGA approved as a Medical Device
BLASTX antimicrobial biofilm wound gel for the management of wounds such as:
Partial and full thickness wounds
Pressure injuries
Diabetic foot and leg wounds
First and second-degree burns
Grafted and donor sites
Surgical site infections
11. Antimicrobial Biofilm Wound Gel
Miller KG et al. Next Science Wound Gel Technology, a Novel Agent That Inhibits Biofilm Development by Gram-Positive and Gram-Negative Wound Pathogens. Antimicrobial Agents and Chemotherapy 2014. 58(6): 3060
DECONSTRUCTS
the biofilm
DESTROYS
pathogens within
the XBIO™ technology
DEFENDS
against recolonisation
Removes metal ions of the
EPS, exposing pathogens
within the biofilm
High osmolarity environment +
antimicrobial surfactant induces
lysis of bacteria within the gel
Biofilm matrix cannot
reform in the presence
of BLASTX
How does BLASTX work?
12. Antimicrobial Biofilm Wound Gel
Miller KG et al. Next Science Wound Gel Technology, a Novel Agent That Inhibits Biofilm Development by Gram-Positive and Gram-Negative Wound Pathogens. Antimicrobial Agents and Chemotherapy 2014. 58(6): 3060
BLASTX in clinic
Biofilm removal + moisture protection promotes healing and reduces risk of scar formation
Non toxic hydrogel – no systemic uptake
Broad spectrum activity for bacteria and fungi
including:
S. aureus, S. epidermidis, P. aeruginosa, A.
baumannii, Klebsiella pneumoniae, MRSA
Deconstructs biofilm, prevents reformation
Retains moist wound environment
Promotes autolytic debridement
Up to 5 days wear time
13. Antimicrobial Biofilm Wound Gel
STEP 2
• Cover with appropriate dressing.
• Do not use alginate dressings.
• Reapply with each dressing change.
BLASTX: How to apply
STEP 1
• Apply BLASTX directly to the wound on a flat surface.
• Apply BLASTX 3mm thick and cover the entire wound
bed to the wound edge.
Best practice wound bed preparation before application
14. Antimicrobial Biofilm Wound Gel
Wolcott, R. (2015). Disrupting the biofilm matrix improves wound healing outcomes. Journal of Wound Care 24(8), 366-71. Kim D, et al.
Wounds. 2018;30(5):120-130. Miller KG et al. Next Science Wound Gel Technology, a Novel Agent That Inhibits Biofilm Development by
Gram-Positive and Gram-Negative Wound Pathogens. Antimicrobial Agents and Chemotherapy 2014. 58(6): 3060 -3072
Broad spectrum efficacy
Combination with Standard of Care
Reduces wound bed volume
Increases wound healing rates
Antimicrobial Biofilm Wound Gel